Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 573 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Novo Nordisk A/S Clear all
Completed Phase 3 Interventional Results available

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

NCT02607865
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, sitagliptin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Tuscumbia, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

NCT04969939
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and placebo 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg, Semaglutide 2.4 mg and placebo 1.0 mg
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Anaheim, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

NCT04606537
View directory record Official record
Conditions
Healthy, Drug Drug Interaction
Interventions
Itraconazole, Rifampin, KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Not applicable Interventional Results available

Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes

NCT03093636
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Continuous Glucose Monitor (CGM)+Decision Support System (DSS), Continuous Glucose Monitor (CGM) alone
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
15 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Stanford, California • New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

NCT06326047
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
NNC0519-0130, Placebo, Trizepatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
55
States / cities
Chula Vista, California • Fresno, California • Inglewood, California + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

NCT03989232
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
61
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes

NCT00611884
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin glargine, insulin degludec, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Inglewood, California • Los Angeles, California • Redlands, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

NCT03926117
View directory record Official record
Conditions
Chronic Kidney Diseases, Inflammation
Interventions
Ziltivekimab
Biological
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
49
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

NCT02054897
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Pell City, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump

NCT00115973
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
pump, insulin aspart
Device · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
30 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Chula Vista, California • Miami, Florida • Witchita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 14, 2026, 2:33 AM EDT
Completed No phase listed Observational

A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists

NCT06322641
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Systemic Inflammation
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 14, 2026, 2:33 AM EDT
Recruiting Phase 3 Interventional

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

NCT07227246
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Recombinant Factor VIIa, Biological/Vaccine: Placebo
Biological
Lead sponsor
Joseph Broderick, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
49
States / cities
Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

NCT02229851
View directory record Official record
Conditions
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions
somapacitan, somatropin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
23 Years to 79 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 14, 2026, 2:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

NCT07444203
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 14, 2026, 2:33 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

NCT05135559
View directory record Official record
Conditions
Haemophilia A and B With and Without Inhibitors
Interventions
Concizumab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
19
States / cities
San Diego, California • Aurora, Colorado • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

NCT02141074
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia B
Interventions
nonacog beta pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 6 Years · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics

NCT00773279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
FlexTouch®, FlexPen®
Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
65
States / cities
Burlingame, California • Concord, California • Encino, California + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

NCT05144984
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
NNC0480-0389, Semaglutide, Placebo (NNC080-0389), Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
71
States / cities
Anniston, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 14, 2026, 2:33 AM EDT
Completed No phase listed Observational

Treatment of Congenital Factor VII Deficiency

NCT01779921
View directory record Official record
Conditions
Congenital Bleeding Disorder, Congenital FVII Deficiency
Interventions
activated recombinant human factor VII, Fresh frozen plasma (Source unspecified), Plasma-derived FVII (LFB), Prothrombin Complex conc. (PCC), Plasma-derived FVII conc. (pdFVII Baxter), Plasma-derived FVII conc. (pdFVII PFL)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

NCT02825251
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Encino, California • Fresno, California • Roseville, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 2 Interventional

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

NCT06064006
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NNC0487-0111, Placebo (NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting

NCT02963935
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo, CMS Intensive Behavior Therapy
Drug · Behavioral
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Jacksonville, Florida • Plantation, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 14, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin

NCT00931476
View directory record Official record
Conditions
Growth Hormone Disorder, Adult Growth Hormone Deficiency, Healthy
Interventions
somatropin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
20 Years to 50 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 14, 2026, 2:33 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

NCT07220564
View directory record Official record
Conditions
Haemophilia A
Interventions
NNC0442-0344 A
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 2:33 AM EDT